View all newsletters
Receive our newsletter - data, insights and analysis delivered to you
August 9, 2010

Partnership to Use Genomic Analysis in Lymphocytic Leukaemia Study

Life Technologies Corporation and Moores Cancer Center at the University of California, San Diego, have come together to use SOLiD 4 genomic analysis to study chronic lymphocytic leukaemia. Researchers from the two organisations plan to use the technology to find potential prognostic bio

By cms admin

Life Technologies Corporation and Moores Cancer Center at the University of California, San Diego, have come together to use SOLiD 4 genomic analysis to study chronic lymphocytic leukaemia.

Researchers from the two organisations plan to use the technology to find potential prognostic biomarkers for chronic lymphocytic leukaemia, and use them to better understand the progression of the disease.

During the first phase of biomarker research, the researchers will study the expression profiles of 96 tumour samples to analyse the biological pathways and molecular mechanisms related to cell-fate decision and disease progression.

The research is being funded by National Institutes of Health.

Defining the biomarkers will be helpful for designing future clinical trials to analyse new treatment options for the disease.

Chronic lymphocytic leukaemia is a cancer of white blood cells that can weaken the immune system and cause bone marrow failure.

Related Companies

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Get important industry news and analysis sent to your inbox
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU

Thank you for subscribing to Hospital Management